Dystrophin Gene

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged lower by more than 50 percent ahead of Friday's market open after the FDA released a briefing document related to the company's Eteplirsen. Sarepta Therapeutics is seeking accelerated approval for eteplirsen for patients with DMD...